Efforts to facilitate patient access to innovative medicines have taken on new urgency in the pandemic era, sharpening drug developers’ focus on the first step in this process: securing regulatory approval.

That focus is particularly keen in Europe, where the European Medicines Agency (EMA) is responsible for determining the benefits and risks of authorizing new treatments.

The push to speed up patient access prompted PRECISIONadvisors to conduct a webinar, moderated by PRECISIONadvisors Director David Carr, which featured a panel of European payers and industry representatives to assess the current regulatory and reimbursement landscape.

Download a summary white paper with key takeaways from the webinar here!